Atherosclerosis: Current status of prevention and treatment

International Journal of Angiology

Volumn 20, Issue 4, 2011, Pages 213-222

  Whayne, Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Atherosclerosis; cholesterol; coronary heart disease; peripheral vascular disease; statins

Indexed keywords

ANACETRAPIB; ANTIOXIDANT; APOLIPOPROTEIN B; APOLIPOPROTEIN E; COLESTIPOL; DALCETRAPIB; EZETIMIBE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OLIVE OIL; PITAVASTATIN; POLICOSANOL; RESVERATROL; ROSUVASTATIN; SOYBEAN PROTEIN; TORCETRAPIB; UBIDECARENONE; UNSATURATED FATTY ACID; VITAMIN D;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DIABETES CONTROL; DIABETES MELLITUS; DIET RESTRICTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TREATMENT FAILURE; EXERCISE; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN TREATMENT; INTENSIVE CARE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MEDITERRANEAN DIET; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; RED WINE; REMISSION; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING CESSATION; THERAPY EFFECT; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 81755188469     PISSN: 10611711     EISSN: 16155939     Source Type: Journal    
DOI: 10.1055/s-0031-1295520     Document Type: Review

References (76)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984 251 3 351-364
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984 251 3 365-374
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 344 8934 1383-1389
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 339 19 1349-1357
5. Downs J R., Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 279 20 1615-1622 (Pubitemid 28248586)
6. Sacks F M., Pfeffer M A., Moye L A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 335 14 1001-1009 (Pubitemid 26338729)
7. Shepherd J, Cobbe S M., Ford I et al, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995 333 20 1301-1307
8. Liao J K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005 45 89-118 (Pubitemid 40261799)
9. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995 91 11 2844-2850
10. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006 37 7 1923-1932 (Pubitemid 44297753)
11. Nissen S E., Nicholls S J., Sipahi I et al, ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 295 13 1556-1565
12. Blankenhorn D H., Johnson R L., Nessim S A., Azen S P., Sanmarco M E., Selzer R H. The Cholesterol Lowering Atherosclerosis Study (CLAS): design, methods, and baseline results. Control Clin Trials 1987 8 4 356-387 (Pubitemid 18040817)
13. Blankenhorn D H., Nessim S A., Johnson R L., Sanmarco M E., Azen S P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987 257 23 3233-3240 (Pubitemid 17078320)
14. Blankenhorn D H., Selzer R H., Mack W J. et al. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Circulation 1992 86 6 1701-1709
15. Brown B G., Zhao X Q., Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 22 1583-1592 (Pubitemid 33126837)
16. Brown G, Albers J J., Fisher L D. et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990 323 19 1289-1298 (Pubitemid 20364735)
17. Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007 192 2 313-322 (Pubitemid 46726333)
18. Falk E, Shah P K., Fuster V. Coronary plaque disruption. Circulation 1995 92 3 657-671
19. Sacks F M., Svetkey L P., Vollmer W M. et al, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001 344 1 3-10 (Pubitemid 32064838)
20. Kastorini C M., Milionis H J., Esposito K, Giugliano D, Goudevenos J A., Panagiotakos D B. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011 57 11 1299-1313
21. Estruch R, Martínez-González M A., Corella D et al, PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006 145 1 1-11 (Pubitemid 46780599)
22. Fitó M, Guxens M, Corella D et al, for the PREDIMED Study Investigators. Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007 167 11 1195-1203 (Pubitemid 46919824)
23. Grundy S M., Cleeman J I., Merz C N. et al, National Heart, Lung, and Blood Institute American College of Cardiology Foundation American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 2 227-239 (Pubitemid 38924592)
24. Wiviott S D., Cannon C P., Morrow D A., Ray K K., Pfeffer M A., Braunwald E, PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005 46 8 1411-1416 (Pubitemid 41446174)
25. Hsia J, MacFadyen J G., Monyak J, Ridker P M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011 57 16 1666-1675
26. Kastelein J J., Akdim F, Stroes E S. et al, ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 358 14 1431-1443 (Pubitemid 351482735)
27. Ridker P M., Danielson E, Fonseca F A. et al, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 21 2195-2207
28. Whayne T F. Jr, Zielke J C., Dickson L G., Winters J L. State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems: LDL apheresis. J Ky Med Assoc 2002 100 12 535-538
29. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003 21 3 199-215 (Pubitemid 37243525)
30. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service: Superintendent of Documents, U.S. Government Printing Office, Washington, D.C., 20402. 1964 1-387
31. Ambrose J A., Barua R S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004 43 10 1731-1737 (Pubitemid 38622506)
32. Benowitz N L. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003 46 1 91-111 (Pubitemid 37013221)
33. Jha P, Jacob B, Gajalakshmi V et al, RGI-CGHR Investigators. A nationally representative case-control study of smoking and death in India. N Engl J Med 2008 358 11 1137-1147 (Pubitemid 351398488)
34. Mulcahy R, Hickey N. Cigarette smoking habits of patients with coronary heart disease. Br Heart J 1966 28 3 404-408
35. Doyle J T., Kannel W B., McNamara P M., Quickenton P, Gordon T. Factors related to suddenness of death from coronary disease: combined Albany-Framingham studies. Am J Cardiol 1976 37 7 1073-1078
36. Shaper A G., Wannamethee S G., Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Int J Epidemiol 2003 32 5 802-808 (Pubitemid 37304644)
37. Barnoya J, Glantz S A. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation 2005 111 20 2684-2698 (Pubitemid 40740869)
38. Cesaroni G, Forastiere F, Agabiti N, Valente P, Zuccaro P, Perucci C A. Effect of the Italian smoking ban on population rates of acute coronary events. Circulation 2008 117 9 1183-1188 (Pubitemid 351544066)
39. Sargent R P., Shepard R M., Glantz S A. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ 2004 328 7446 977-980 (Pubitemid 38530365)
40. Leng G C., Lee A J., Fowkes F G., Lowe G D., Housley E. The relationship between cigarette smoking and cardiovascular risk factors in peripheral arterial disease compared with ischaemic heart disease. The Edinburgh Artery Study. Eur Heart J 1995 16 11 1542-1548 (Pubitemid 26037783)
41. Critchley J A., Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA 2003 290 1 86-97 (Pubitemid 37432870)
42. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987 221 3 253-260 (Pubitemid 17069424)
43. McRobbie H, Thornley S. [The importance of treating tobacco dependence]. Rev Esp Cardiol 2008 61 6 620-628
44. The Seventh Report of the Joint National Committee on Prevention. Detection, Evaluation, and Treatment of High Blood Pressure: U.S. Department of Health and Human Services. 2004 1-86
45. Wang Y, Wang Q J. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med 2004 164 19 2126-2134 (Pubitemid 39410802)
46. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002 360 9349 1903-1913 (Pubitemid 35472129)
47. Levy D, Merz C N., Cody R J. et al. Hypertension detection, treatment and control: a call to action for cardiovascular specialists. J Am Coll Cardiol 1999 34 4 1360-1362 (Pubitemid 29500570)
48. Doumas M, Papademetriou V, Douma S et al. Benefits from treatment and control of patients with resistant hypertension. Int J Hypertens 2011 2011 318-549
49. Perry H M. Jr, Davis B R., Price T R. et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000 284 4 465-471 (Pubitemid 30484480)
50. Staessen J A., Thijisq L, Fagard R et al, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004 22 4 847-857 (Pubitemid 38543578)
51. Grundy S M., Cleeman J I., Daniels S R. et al, American Heart Association National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 17 2735-2752 (Pubitemid 41532612)
52. Whayne T F. Jr. In defense of the metabolic syndrome. J Clin Lipidol 2009 3 4 247-249
53. NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. May 26, 2011 Available at: http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id= 2792
54. Clofibrate and niacin in coronary heart disease. JAMA 1975 231 4 360-381
55. Patel A, MacMahon S, Chalmers J et al, ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 24 2560-2572 (Pubitemid 351831357)
56. Gerstein H C., Miller M E., Byington R P. et al, Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 24 2545-2559 (Pubitemid 351831356)
57. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 14 977-986
58. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care 2003 26 (Suppl 1) S25-S27
59. Leitzmann M F., Park Y, Blair A et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007 167 22 2453-2460 (Pubitemid 350254904)
60. Kujala U M., Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality: the Finnish twin cohort. JAMA 1998 279 6 440-444 (Pubitemid 28082253)
61. Hakim A A., Curb J D., Petrovitch H et al. Effects of walking on coronary heart disease in elderly men: the Honolulu Heart Program. Circulation 1999 100 1 9-13 (Pubitemid 29297933)
62. Franco O H., de Laet C, Peeters A, Jonker J, Mackenbach J, Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med 2005 165 20 2355-2360 (Pubitemid 41640847)
63. Bijnen F C., Caspersen C J., Feskens E J., Saris W H., Mosterd W L., Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: The Zutphen Elderly Study. Arch Intern Med 1998 158 14 1499-1505 (Pubitemid 28340982)
64. Thompson P D., Buchner D, Pina I L. et al, American Heart Association Council on Clinical Cardiology Subcommittee on Exercise, Rehabilitation, and Prevention American Heart Association Council on Nutrition, Physical Activity, and Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003 107 24 3109-3116 (Pubitemid 36758987)
65. Lakka T A., Lakka H M., Rankinen T et al. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005 26 19 2018-2025 (Pubitemid 41435729)
66. Howard A A., Arnsten J H., Gourevitch M N. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med 2004 140 3 211-219
67. Wallerath T, Poleo D, Li H, Förstermann U. Red wine increases the expression of human endothelial nitric oxide synthase: a mechanism that may contribute to its beneficial cardiovascular effects. J Am Coll Cardiol 2003 41 3 471-478 (Pubitemid 36164505)
68. Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNFalpha and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009 29 8 1164-1171
69. Fisher N D., Hughes M, Gerhard-Herman M, Hollenberg N K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 2003 21 12 2281-2286 (Pubitemid 38293567)
70. Maron D J. Flavonoids for reduction of atherosclerotic risk. Curr Atheroscler Rep 2004 6 1 73-78 (Pubitemid 38898913)
71. Paolini J F., Mitchel Y B., Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008 101 5 625-630
72. Barter P J., Caulfield M, Eriksson M et al, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 21 2109-2122 (Pubitemid 350146106)
73. Yvan-Charvet L, Kling J, Pagler T et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 2010 30 7 1430-1438
74. Stein E A., Roth E M., Rhyne J M., Burgess T, Kallend D, Robinson J G. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010 31 4 480-488
75. Whayne T F. Jr. What should medical practitioners know about the role of alternative medicines in cardiovascular disease management? Cardiovasc Ther 2010 28 2 106-123
76. Whayne T F. Vitamin D: popular cardiovascular supplement but benefit must be evaluated. Int J Angiol 2011 20 2 63-72